<DOC>
	<DOCNO>NCT01500993</DOCNO>
	<brief_summary>This study compare capecitabine standard 5-FU perioperative treament locally advanced rectal cancer .</brief_summary>
	<brief_title>Capecitabine Perioperative Treatment Rectal Cancer</brief_title>
	<detailed_description>5-Fluorouracil ( 5-FU ) base chemoradiotherapy ( CRT ) regard standard perioperative treatment locally advanced rectal cancer ( LARC ) . We investigate replacement 5-FU oral pro-drug capecitabine ( cape ) within randomize phase III trial . Patients age ≥18 year LARC stage II III recruit two-arm , two-cohort randomize non-inferiority phase-III trial ( arm A : cape , arm B : 5-FU ; cohort [ C ] I : adjuvant , C II : neoadjuvant ) . Regimens : Arm A : CRT : 50.4 Gy + cape 1,650 mg/m² day 1-38 plus five cycle cape 2,500 mg/m² 1-14 , repeat 22 ( C I : 2 x cape , CRT , 3 x cape ; C II : CRT , TME surgery follow cape x 5 ) . Arm B : CRT : 50.4 Gy + infusional 5-FU 225 mg/m² daily [ C I ] infusional 5-FU 1,000 mg/m² 1-5 29-33 [ C II ] plus 4 cycle bolus 5-FU 500mg/m² 1-5 , repeat 29 ( C I : 2 x 5-FU , CRT , 2 x 5-FU ; C II : CRT , TME surgery follow 5-FU x 4 ) . Primary endpoint 5-year overall survival ( OS ) , secondary endpoint comprise 3-year disease-free survival ( DFS ) safety . The study design investigate whether 5- year overall survival rate ( SR5 ) non-inferior arm A versus arm B . We hypothesize SR5 standard arm B 57.5 % . Sample size calculation perform power 80 % type I error 5 % drop-out rate 5 % . Therefore , total least 372 evaluable patient ( i.e . 186 per arm ) require confirm non-inferiority experimental arm A non-inferiority margin maximal 12.5 % median follow-up time 48 month .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Eligible patient 18 year old histologically confirm adenocarcinoma rectum ( defined distal border tumour le 16 cm anal verge measure rigid rectoscopy ) evidence distant metastasis ( identify abdominal ultrasound CT scan chest radiography ) . Patients adjuvant cohort undergone R0resection total mesorectal excision ( TME ) pT34 Nany Tany Npositive nonmetastatic rectal cancer . Patients treat neoadjuvant cohort need clinical T34 Nany Tany Npositive tumour stag endoscopic ultrasound , provide low border tumour locate 0 16 cm anal verge measure rigid rectoscopy primary tumour deem resectable TME surgery basis clinical assessment . Other eligibility criterion comprise : WHO status zero one ; adequate liver , renal , bone marrow function define follow : leucocyte count &gt; 3,500/µl , thrombocyte count &gt; 100,000/µl , hemoglobin &gt; 10.0 g/dl ; serum bilirubine &lt; 2.0 mg/dl , serum creatinine &lt; 2.0 mg/dl . Exclusion criterion : Prior treatment rectal cancer , prior chemo immunotherapy , prior pelvic radiotherapy , history malignant disease within past five year exception succesfully treat basal carcinoma skin carcinoma situ uterine cervix . Participation another trial , pregnancy , breastfeeding , unwillingness use effective contraception , medical condition concomitant illness could potentially interfere compliance protocol regard exclusion criterion , well .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>phase-III trial</keyword>
</DOC>